AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (NASDAQ: AXSM)
July 06, 2022 01:30 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Axsome Therapeutics? If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
July 04, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, July 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm
June 29, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important July 12 Deadline in Securities Class Action – AXSM
June 25, 2022 12:18 ET
|
The Rosen Law Firm PA
NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Axsome, Pegasystems, Humbl, and Okta and Encourages Investors to Contact the Firm
June 24, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
June 19, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm
June 13, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Upstart, Oscar, Axsome, and Humbl and Encourages Investors to Contact the Firm
June 08, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oscar Health, Axsome, Humbl, and Okta and Encourages Investors to Contact the Firm
June 03, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
June 02, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
AXS-05 rapidly and significantly improved anhedonic symptoms, measured by the MADRS anhedonia subscale, starting 1 week after treatment Data being presented at the American Society of Clinical...